All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Subcutaneous Daratumumab Approaches EU Approval in High-Risk Smoldering Myeloma

June 20th 2025

The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

June 20th 2025

Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.

UM171 Cell Therapy Earns Positive CHMP Opinion for Hematological Malignancies

June 20th 2025

The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.

Darolutamide Plus ADT Earns Positive Opinion for European Approval From CHMP in Metastatic Hormone-Sensitive Prostate Cancer

June 20th 2025

The European Medicines Agency’s CHMP has recommended the approval of darolutamide plus ADT in mHSPC in the European Union.

Nirogacestat Awaits Review Following Positive CHMP Opinion for Desmoid Tumors

June 20th 2025

The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.

CHMP Recommends EU Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

June 20th 2025

The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

CHMP Recommends Ibrutinib Plus Chemoimmunotherapy for Frontline, Transplant-Eligible Mantle Cell Lymphoma

June 20th 2025

CHMP recommended ibrutinib plus immunochemotherapy for previously untreated, transplant-eligible mantle cell lymphoma.

Science Clears the Way to Treating the Trickiest Bladder Cancers

June 20th 2025

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

First-in-Human Data Support CISH Knockout Strategy to Enhance TIL Activity, Circumvent ICI Resistance in Metastatic GI Cancers

June 20th 2025

Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.

Pembrolizumab Plus Chemoradiation Hits ORR End Point in Unresectable Vulvar Cancer

June 20th 2025

Pembrolizumab plus chemoradiation with maintenance pembrolizumab was safe and effective in unresectable vulvar cancer.

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

June 19th 2025

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

BGB-16673 Displays a High ORR and Tolerability in Waldenström Macroglobulinemia

June 19th 2025

BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.

Roswell Park’s Dr. Sai Yendamuri Elected to the American Surgical Association

June 19th 2025

Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization

Updated Data From Phase 1 Trials Support Shifts in the Lung Cancer Treatment Paradigm

June 19th 2025

Martin E. Gutierrez, MD, discusses steps towards a continuous shift in both the NSCLC and SCLC treatment paradigms, based on trials presented at ASCO 2025.

PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test

June 19th 2025

Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.

Health Canada Approves Adjuvant Ribociclib for HR+/HER2– Early Breast Cancer

June 19th 2025

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Choosing Clinical End Points in China for US Bridging Studies

June 19th 2025

Evan S. Wu, MD, PhD, delves into the one of the most pivotal aspects of designing a successful bridging study: the selection of clinical end points.

Timing of ESR1 Mutation Testing Is Critical to Overcome Adaptive Endocrine Resistance in HR+ Breast Cancer

June 19th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses how findings from SERENA-6 reinforce the importance of timely ESR1 testing in HR-positive breast cancer.

Telisotuzumab Vedotin Maintains Efficacy Across Key Subgroups in Pretreated NSCLC With c-MET Overexpression

June 19th 2025

Joshua K. Sabari, MD, discusses the role of telisotuzumab vedotin in patients with locally advanced/metastatic NSCLC with c-MET overexpression.

T-DXd Plus Pertuzumab Could Add to Antibody-Drug Conjugate Arsenal in HER2+ Breast Cancer

June 18th 2025

Sarah Sammons, MD, discusses data with T-DXd in frontline HER2-positive breast cancer and other ADCs in the breast cancer space.